Company Description
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States.
Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders.
It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan.
aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2005 |
| IPO Date | May 7, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Sanjay Shukla |
Contact Details
Address: 10240 Sorrento Valley Road, Suite 300 San Diego, California 92121 United States | |
| Phone | 858 731 8389 |
| Website | atyrpharma.com |
Stock Details
| Ticker Symbol | ATYR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001339970 |
| ISIN Number | US0021202025 |
| Employer ID | 20-3435077 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sanjay S. Shukla M.D., M.S. | President, Chief Executive Officer and Director |
| Xiang-Lei Yang Ph.D. | Founder |
| Dr. Jayant Aphale MBA, Ph.D. | Vice President of Technical Operations |
| Ashlee Dunston | Director of Investor Relations and Corporate Communications |
| Peter Villiger | Vice President of Corporate Development |
| Danielle Campbell | Vice President of Human Resource |
| Dr. Leslie Nangle Ph.D. | Vice President of Research |
| Dr. Ying J. Buechler Ph.D. | Executive Director of Biologics Development and Manufacturing |
| Dr. David J. King Ph.D. | Scientific Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 15, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Aug 13, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 13, 2024 | 10-Q | Quarterly Report |
| Aug 13, 2024 | 8-K | Current Report |
| Jul 22, 2024 | 8-K | Current Report |
| Jun 25, 2024 | UPLOAD | Filing |